Analysis of Glycotest Licenses Novel Biomarker Intellectual Property from the Medical University of South Carolina to Advance Next-Generation Liver Fibrosis Staging Test - aVenture Research
BioQuick News
Glycotest Licenses Novel Biomarker Intellectual Property from the Medical University of South Carolina to Advance Next-Generation Liver Fibrosis Staging Test
On October 13, 2026, Glycotest, Inc. announced that it has executed a license agreement with the Zucker Institute for Innovation Commercialization (ZI), the commercialization entity advancing technologies originated from the Medical University of South Carolina (MUSC), for intellectual property relating to Glycotest’s blood test for staging liver fibrosis. The licensed IP supports the expansion of ... Full Story
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.